April 2021 in “Journal of Investigative Dermatology” A trial showed that a new treatment is safe and effective for male pattern baldness, with most participants growing new hair.
April 2020 in “Journal of the Endocrine Society” Male pattern baldness may indicate arterial stiffness in transgender men on long-term testosterone therapy.
Male pattern baldness is a common hair loss in men caused by genetics and hormones, with treatments including drugs, hair transplants, and hair loss products.
January 2018 in “프로그램북(구 초록집)” Botulinum toxin type A is a safe and effective treatment for male pattern baldness.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Male-pattern baldness has a weak link to heart disease and some related health conditions.
August 2016 in “Journal of Investigative Dermatology” Different levels of microRNAs in different parts of the scalp can cause male pattern baldness.
July 2016 in “Cancer Research” Male pattern baldness is linked to a higher risk of certain skin cancers, especially on the scalp.
November 2015 in “Hair transplant forum international” PRP may help with hair regrowth in male pattern baldness, but more research is needed.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
Targeting a specific lipid could help treat male pattern baldness.
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
January 2012 in “Chinese Journal of Aesthetic Medicine” Increased androgen receptor expression in certain hair follicle areas may cause male pattern baldness.
September 2011 in “Hair transplant forum international” Hair transplants can be effective for early male pattern baldness.
Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.
January 2009 in “Revista de Ciências Médicas” Male pattern baldness is a genetic condition causing hair loss, with limited but improving treatment options.
January 2007 in “Annals of The Royal College of Surgeons of England” Removing a hormone-producing adrenal tumor can stop hair loss in women with high testosterone levels.
January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
May 2004 in “Dermatologic Surgery” Most men stopped using finasteride for baldness due to unsatisfactory results or were lost to follow-up, and those who continued saw minimal to moderate improvement.
January 2001 in “Chinese Journal of Medical Aesthetics and Cosmetology” Micrografts can grow natural hair and most patients are satisfied, but some need multiple procedures.
Surgical treatments like hair transplants can help with male pattern baldness.
February 2023 in “Cureus” Male pattern baldness in medical students is linked to higher depression, loneliness, and internet addiction.
August 2021 in “Journal of The American Academy of Dermatology” Finasteride treatment changes hormone levels in male pattern baldness patients.
June 2017 in “IP Indian journal of clinical and experimental dermatology” Using 10% topical minoxidil, oral finasteride, and microneedling together can effectively treat Male Pattern Baldness with high patient satisfaction and no major side effects.
November 2023 in “Plastic and Reconstructive Surgery – Global Open” Americans see hair transplants as valuable for treating hair loss and want them to be more affordable and tailored to each gender.
March 2020 in “Zenodo (CERN European Organization for Nuclear Research)” February 2020 in “Zenodo (CERN European Organization for Nuclear Research)” January 2000 in “Hair and its disorders: biology, pathology and management, 2000, ISBN 1853177997, págs. 137-152”